
================================================================================
=== DOCUMENT 1: 8-K - tm2516273d1_8k.htm ===
================================================================================

false
0001075415
0001075415
2025-05-29
2025-05-29
0001075415
us-gaap:CommonStockMember
2025-05-29
2025-05-29
0001075415
DHC:SeniorNotesDue2042Member
2025-05-29
2025-05-29
0001075415
DHC:SeniorNotesDue2046Member
2025-05-29
2025-05-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 29, 2025
Diversified Healthcare Trust
(Exact Name of Registrant as Specified in
Its Charter)
Maryland
(State or Other Jurisdiction of Incorporation)
001-15319
04-3445278
(Commission File Number)
(IRS Employer Identification No.)
Two Newton Place
,
255 Washington Street
,
Suite 300
Newton
,
Massachusetts
02458-1634
(Address of Principal Executive Offices)
(Zip Code)
617
-
796-8350
(Registrant’s Telephone Number, Including
Area Code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title Of Each Class
Trading Symbol(s)
Name Of Each Exchange
On
Which Registered
Common
Shares of Beneficial Interest
DHC
The
Nasdaq Stock Market LLC
5.625%
Senior Notes due 2042
DHCNI
The
Nasdaq Stock Market LLC
6.25%
Senior Notes due 2046
DHCNL
The
Nasdaq Stock Market LLC
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
In this Current Report on Form 8-K, the term “the Company” refers to Diversified Healthcare Trust.
Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As described in Item 5.07 below, at the Company’s
annual meeting of shareholders held on May 29, 2025 (the “Annual Meeting”), the Company’s shareholders approved the
Diversified Healthcare Trust Second Amended and Restated 2012 Equity Compensation Plan (the “Equity Compensation Plan”), which
amended and restated the Company’s existing Amended and Restated 2012 Equity Compensation Plan to increase by 3,500,000 the total
number of common shares of beneficial interest, $.01 par value per share, available for awards and to extend the term of the plan until May 29,
2035, the tenth anniversary of the Annual Meeting. The Company's Trustees and officers, employees of The RMR Group LLC, consultants, advisors and
other persons or entities providing management, administrative or other services to us or to our subsidiaries are eligible to receive
awards under the Equity Compensation Plan.
A copy of the Equity Compensation Plan that was
approved by the Company’s shareholders was included as Annex A to the Company’s proxy statement for the Annual Meeting, which
proxy statement was filed with the Securities and Exchange Commission (the “SEC”) on March 20, 2025 (the “2025 Proxy
Statement”), and is available at the SEC’s website at www.sec.gov. The terms and conditions of the Equity Compensation Plan
are described in detail in the 2025 Proxy Statement. The foregoing description of the Equity Compensation Plan is qualified in its entirety
by the terms of the Equity Compensation Plan. A copy of the Equity Compensation Plan is filed as Exhibit 10.1 hereto and is incorporated
by reference herein.
Item 5.07.
Submission of Matters to a Vote of Security Holders.
At
the Annual Meeting, the Company’s shareholders voted on the election of seven Trustees
to the Company’s Board of Trustees
each for a one year term of office continuing until the Company’s 2026 annual meeting of shareholders and until her, his or their
respective successor is duly elected and qualifies. The following persons were elected as Trustees and received the following votes:
Nominee
Votes For
Withhold
Broker
Non-Votes
Christopher J. Bilotto
166,303,992
4,876,315
30,246,011
Alan Felder
166,835,261
4,345,046
30,246,011
Lisa Harris Jones
144,391,470
26,788,837
30,246,011
Phyllis M. Hollis
165,010,370
6,169,937
30,246,011
Dawn K. Neher
165,297,938
5,882,369
30,246,011
Adam Portnoy
134,285,987
36,894,320
30,246,011
Jeffrey P. Somers
131,452,805
39,727,502
30,246,011
The Company’s
shareholders also voted on a non-binding advisory resolution on the compensation paid to the Company’s named executive officers
as disclosed pursuant to Item 402 of Regulation S-K in the 2025 Proxy Statement
. This proposal received the following votes:
For
Against
Abstain
Broker Non-Votes
162,374,717
8,618,238
187,352
30,246,011
As described above in Item 5.02, the Company’s shareholders also
voted on the approval of the Equity Compensation Plan. This proposal received the following votes:
For
Against
Abstain
Broker Non-Votes
164,766,615
6,237,228
176,464
30,246,011
The Company’s
shareholders also ratified the appointment of
Deloitte & Touche LLP as the Company’s independent auditors to serve for
the 2025 fiscal year. This proposal received the following votes:
For
Against
Abstain
Broker Non-Votes
199,066,139
2,225,458
134,721
N/A
The results reported above are final voting results.
Item 9.01.
Financial Statements and Exhibits.
Exhibit
Number
Description
10.1
Diversified Healthcare Trust Second Amended and Restated 2012 Equity Compensation Plan (Filed herewith)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DIVERSIFIED HEALTHCARE TRUST
By:
/s/
Matthew C. Brown
Name:
Matthew C. Brown
Title:
Chief Financial Officer and Treasurer
Date: June 2, 2025

